Lipophilic iron chelators as potential therapeutic agents in Parkinson's disease [ 2014 - 2017 ]

Research Grant

Researchers: Prof Rachel Codd (Principal investigator) ,  A/Pr Kay Double ,  A/Pr Paul Witting ,  Dr Jeffrey Liddell

Brief description The impaired coordination and tremors experienced by the 64,000 Australians with Parkinson’s disease make managing life at work and home difficult. With 240,000 Australians projected to be living with Parkinson’s disease by 2033, the discovery of agents that slow or stop disease progression is urgent. Iron in the brain has been implicated in Parkinson’s disease. In this project, the performance of new low toxicity agents in altering brain iron distribution will be studied as potential drugs for Parkinson’s disease.

Funding Amount $AUD 616,537.85

Funding Scheme Project Grants

Notes Standard Project Grant